Literature DB >> 20733154

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

Alison J Moskowitz1, Joachim Yahalom, Tarun Kewalramani, Jocelyn C Maragulia, Jill M Vanak, Andrew D Zelenetz, Craig H Moskowitz.   

Abstract

To identify prognostic factors for patients transplanted for relapsed or refractory Hodgkin lymphoma we carried out a combined analysis of patients followed prospectively on 3 consecutive protocols at Memorial Sloan-Kettering Cancer Center. One hundred fifty-three patients with chemosensitive disease after ICE (ifosfamide, carboplatin, and etoposide)-based salvage therapy (ST) proceeded to high-dose chemoradiotherapy followed by autologous stem cell transplantation (ASCT). Patients were evaluated with computed tomography and functional imaging (gallium or fluorodeoxyglucose-positron emission tomography) prior to ST and again before ASCT. Functional imaging status before ASCT was the only factor significant for event-free survival (EFS) and overall survival by multivariate analysis and clearly identifies poor risk patients (5-year EFS 31% and 75% for FI-positive and negative patients respectively). Administration of involved-field radiotherapy with ASCT was marginally significant for EFS (P = .055). Studies evaluating novel STs, conditioning regimens, post-ASCT maintenance, or allogeneic stem cell transplantation are warranted for patients who fail to normalize pre-ASCT functional imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733154      PMCID: PMC3799204          DOI: 10.1182/blood-2010-05-282756

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

Authors:  Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Peter Vandenberghe; Johan Maertens; Guy Bormans; José Thomas; Jan Balzarini; Christine De Wolf-Peeters; Luc Mortelmans; Gregor Verhoef
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

2.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

3.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Authors:  C H Moskowitz; S D Nimer; A D Zelenetz; T Trippett; E E Hedrick; D A Filippa; D Louie; M Gonzales; J Walits; N Coady-Lyons; J Qin; R Frank; J R Bertino; A Goy; A Noy; J P O'Brien; D Straus; C S Portlock; J Yahalom
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

5.  Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.

Authors:  A Becherer; M Mitterbauer; U Jaeger; P Kalhs; H T Greinix; G Karanikas; C Pötzi; M Raderer; R Dudczak; K Kletter
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

6.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

7.  Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

Authors:  Bart W Schot; Josée M Zijlstra; Wim J Sluiter; Gustaaf W van Imhoff; Jan Pruim; Willem Vaalburg; Edo Vellenga
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

8.  Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

Authors:  Elias Jabbour; Chitra Hosing; Gregory Ayers; Rodolfo Nunez; Paolo Anderlini; Barbara Pro; Issa Khouri; Anas Younes; Fredrick Hagemeister; Larry Kwak; Luis Fayad
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

9.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

10.  Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.

Authors:  Roberto Crocchiolo; Carla Canevari; Andrea Assanelli; Francesca Lunghi; Michela Tassara; Maria Lupo Stanghellini; Daniela Clerici; Claudio Landoni; Paolo Servida; Massimo Bernardi; Jacopo Peccatori; Andres Ferreri; Luigi Gianolli; Claudio Bordignon; Federico Caligaris-Cappio; Fabio Ciceri; Ferruccio Fazio
Journal:  Leuk Lymphoma       Date:  2008-04
View more
  74 in total

1.  Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.

Authors:  Raynier Devillier; Diane Coso; Luca Castagna; Isabelle Brenot Rossi; Antonella Anastasia; Arturo Chiti; Vadim Ivanov; Jean Marc Schiano; Armando Santoro; Christian Chabannon; Monica Balzarotti; Didier Blaise; Reda Bouabdallah
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 2.  How I treat advanced Hodgkin lymphoma - a global view.

Authors:  Peter Hokland; Mansi Shah; Kevin David; Andrew Evens; Rebecca Auer; Rifca Ledieu; Stefanie Kreissl; Paul J Bröckelmann; Peter Borchmann; Anu Korula; Vikram Mathews; Weerapat Owattanapanich; Judith Trotman
Journal:  Br J Haematol       Date:  2020-06-19       Impact factor: 6.998

Review 3.  Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

Authors:  Alison J Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Authors:  Ann S LaCasce; R Gregory Bociek; Ahmed Sawas; Paolo Caimi; Edward Agura; Jeffrey Matous; Stephen M Ansell; Howland E Crosswell; Miguel Islas-Ohlmayer; Caroline Behler; Eric Cheung; Andres Forero-Torres; Julie Vose; Owen A O'Connor; Neil Josephson; Yinghui Wang; Ranjana Advani
Journal:  Blood       Date:  2018-04-27       Impact factor: 22.113

Review 5.  The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma.

Authors:  Leona Holmberg; David G Maloney
Journal:  J Natl Compr Canc Netw       Date:  2011-09-01       Impact factor: 11.908

6.  Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

Authors:  Jacob P Smeltzer; Amanda F Cashen; Qin Zhang; Andrew Homb; Farrokh Dehdashti; Camille N Abboud; John F Dipersio; Keith E Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; Nancy L Bartlett; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-03       Impact factor: 5.742

Review 7.  The role of autologous transplantation in Hodgkin lymphoma.

Authors:  Bastian von Tresckow; Andreas Engert
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

Review 8.  A Review of Autologous Stem Cell Transplantation in Lymphoma.

Authors:  Umar Zahid; Faisal Akbar; Akshay Amaraneni; Muhammad Husnain; Onyee Chan; Irbaz Bin Riaz; Ali McBride; Ahmad Iftikhar; Faiz Anwer
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

9.  Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

Authors:  Gary A Ulaner; Debra A Goldman; Craig S Sauter; Jocelyn Migliacci; Joshua Lilienstein; Mithat Gönen; Heiko Schöder; Craig H Moskowitz; Andrew D Zelenetz
Journal:  Radiology       Date:  2015-06-02       Impact factor: 11.105

10.  Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

Authors:  P Satwani; Z Jin; P L Martin; M Bhatia; J H Garvin; D George; S Chaudhury; J Talano; E Morris; L Harrison; J Sosna; M Peterson; O Militano; S Foley; J Kurtzberg; M S Cairo
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.